SUTRO BIOPHARMA, INC.

Sutro Biopharma (STRO) has reported zero cyber incidents and zero red-flag 8-K filings over the past 90 days, indicating stable near-term operational continuity. However, a short observation window provides limited visibility into structural risk—the company remains a clinical-stage biotech with typical exposure to financing cycles, equity dilution, and clinical development setbacks. Our 90-day snapshot cannot capture the full context of its capital raising history, stockholder dilution patterns, or multi-year operational sustainability. The full $49 Report extends analysis to 12 months of filings, calculates dilution risk scoring, maps financing dependency, and flags AI-identified risk signals across the company's broader financial narrative.